{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Administered+via+subcutaneous+injection%29&page=3", "query": { "intervention": "Placebo (Administered via subcutaneous injection)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 93, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Administered+via+subcutaneous+injection%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Administered+via+subcutaneous+injection%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T23:22:44.045Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02889796", "title": "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo to match adalimumab", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1759, "start_date": "2016-08-30", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Hemet", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02889796" }, { "nct_id": "NCT05854381", "title": "To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV I Infection" ], "interventions": [ { "name": "VIR-1388", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 93, "start_date": "2023-09-19", "completion_date": "2025-11-19", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05854381" }, { "nct_id": "NCT04615273", "title": "A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Growth Hormone Deficiency", "Endocrine System Diseases", "Hormone Deficiency" ], "interventions": [ { "name": "Lonapegsomatropin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Somatropin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ascendis Pharma Endocrinology Division A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "23 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "23 Years to 80 Years" }, "enrollment_count": 264, "start_date": "2020-12-03", "completion_date": "2023-12-01", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04615273" }, { "nct_id": "NCT06973109", "title": "Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoporosis, Post-menopausal" ], "interventions": [ { "name": "Romosozumab", "type": "DRUG" }, { "name": "Alendronate (Fosamax)", "type": "DRUG" }, { "name": "Placebo Romosozumab", "type": "DRUG" }, { "name": "Placebo Alendronate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "FEMALE", "summary": "65 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2026-06-20", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973109" }, { "nct_id": "NCT07590193", "title": "A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "AMG 127", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 162, "start_date": "2026-06-11", "completion_date": "2027-10-02", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 2, "location_summary": "Lake Forest, California • Aventura, Florida", "locations": [ { "city": "Lake Forest", "state": "California" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07590193" }, { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT02420353", "title": "Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rupture of Anterior Cruciate Ligament" ], "interventions": [ { "name": "Somatropin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 20, "start_date": "2015-05", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2020-01-06", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420353" }, { "nct_id": "NCT01151423", "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Thrombotic Thrombocytopenic Purpura" ], "interventions": [ { "name": "Caplacizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ablynx, a Sanofi company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2011-01", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 13, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01151423" }, { "nct_id": "NCT02760407", "title": "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Olokizumab 64mg q4w", "type": "DRUG" }, { "name": "Olokizumab 64mg q2w", "type": "DRUG" }, { "name": "Adalimumab 40mg q2w", "type": "DRUG" }, { "name": "Placebo q2w", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm International, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1648, "start_date": "2016-06-06", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 64, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760407" }, { "nct_id": "NCT05293171", "title": "Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "1.25 mg/kg BL-8040 + BL-8040-matching placebo", "type": "DRUG" }, { "name": "2 mg/kg BL-8040", "type": "DRUG" }, { "name": "BL-8040-matching placebo", "type": "DRUG" }, { "name": "400 mg Moxifloxacin (1x400 mg tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2021-06-11", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-06T23:22:44.045Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293171" } ] }